Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DNA vaccine study backs electroporation technology:

This article was originally published in Clinica

Executive Summary

Animal trial results for Genetronics Biomedical's electroporation technique for enhancing the efficacy of DNA vaccines continue to show promise, the San Diego, California firm has reported. In a study performed in collaboration with Chiron, electroporation-enhanced DNA vaccination was found to provide faster, stronger, and longer-lasting antibody and cellular immune responses. Presented at this month's American Society of Gene Therapy meeting in Minneapolis, Minnesota, the results indicated that an electroporation regimen using Genetronics' technology provided antibody levels in rabbits equivalent to levels of more invasive, earlier-generation electroporation equipment, the company said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel